Drug companies are being temporarily allowed to readjust their adverse event reporting priorities in the EU to give the highest precedence to serious incidents associated with medicinal products used for treating or preventing COVID-19.
This temporary mechanism of prioritizing which suspected adverse reactions or individual case safety reports (ICSRs) should be first reported to...




